Last reviewed · How we verify

Innocoll — Portfolio Competitive Intelligence Brief

Innocoll pipeline: 2 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bupivacaine Hydrochloride And Epinephrine BUPIVACAINE marketed Amide Local Anesthetic Cytochrome P450 2D6 Ophthalmology 1972-01-01
XaraColl XaraColl marketed Bioabsorbable hemostatic and antimicrobial wound matrix Chlorhexidine (broad-spectrum antimicrobial); collagen matrix (hemostatic scaffold) Surgery/Wound Management
Bupivacaine HCl collagen-matrix implant Bupivacaine HCl collagen-matrix implant phase 3 Local anesthetic Voltage-gated sodium channels Pain management / Surgery
Bupivacaine HCl infiltration Bupivacaine HCl infiltration phase 3 Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 3 shared drug classes
  2. University of California, San Francisco · 2 shared drug classes
  3. Ain Shams Maternity Hospital · 1 shared drug class
  4. Aligarh Muslim University · 1 shared drug class
  5. Allergan · 1 shared drug class
  6. Atlantic Health System · 1 shared drug class
  7. Aultman Health Foundation · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Innocoll:

Cite this brief

Drug Landscape (2026). Innocoll — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/innocoll. Accessed 2026-05-14.

Related